Amazing to see recent NICE approvals:
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
December 21, 2024 at 10:43 AM
Amazing to see recent NICE approvals:
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
Gearing up mRNA vaccines ("tolerogenic") to prevent autoimmune diseases, vital science that is currently under irrational and reckless attack
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 within lipid nanoparticles - Nature Biomedical Engineering
Therapeutic tolerogenic antigen-presenting cells can be generated in vivo by delivering, via lipid nanoparticles, mRNA coding for the inhibitory protein programmed death ligand 1, as shown in mouse mo...
www.nature.com
March 28, 2025 at 3:11 PM
Gearing up mRNA vaccines ("tolerogenic") to prevent autoimmune diseases, vital science that is currently under irrational and reckless attack
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Vermutlich ist es ein "Klassen-Effekt" der mRNA-LNP Plattform. Diese führt zu einer Aktivierung des angeborenen Immunsystems, was sekundär CD8 T Zellantworten verstärkt. Der beobachtete Effekt war in Kombination mit einer Checkpunkt-Blockade (PDL1-Antikörper) bei NSCLC und Melanom.
October 22, 2025 at 8:56 PM
Vermutlich ist es ein "Klassen-Effekt" der mRNA-LNP Plattform. Diese führt zu einer Aktivierung des angeborenen Immunsystems, was sekundär CD8 T Zellantworten verstärkt. Der beobachtete Effekt war in Kombination mit einer Checkpunkt-Blockade (PDL1-Antikörper) bei NSCLC und Melanom.
It was such a great pleasure to present about KRAS, STK11, Low PDL1 challenges and be part of MaTOS24 Masters of Thoracic Oncology.
November 25, 2024 at 12:39 AM
It was such a great pleasure to present about KRAS, STK11, Low PDL1 challenges and be part of MaTOS24 Masters of Thoracic Oncology.
@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25
March 5, 2025 at 12:09 PM
@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25
'The turning point was a meeting of the Soc. for the Biological Therapy of Cancer (...) I had been invited to organize a workshop and asked along my Genentech coll. Mark Sliwkowski(...) We heard Suzanne Topalian talk about the first Medarex trials of PD1 & PDL1 inhibitors' #Immunology #Immunotherapy
Keeping the immuno-oncology flame burning
Ira Mellman, the new president of research at the Parker Institute for Cancer Immunotherapy, asks why so many drug developers are retreating from immune-modulating drugs, cell therapies and cancer vac...
www.nature.com
June 15, 2025 at 11:27 AM
'The turning point was a meeting of the Soc. for the Biological Therapy of Cancer (...) I had been invited to organize a workshop and asked along my Genentech coll. Mark Sliwkowski(...) We heard Suzanne Topalian talk about the first Medarex trials of PD1 & PDL1 inhibitors' #Immunology #Immunotherapy
Congratulations to Adel from @petermac for this analysis showing KRAS G12D patients are more likely to be non-smokers but also associated with low PDL1, comutations with TP53/STK11 and derive limited immunotherapy response. Area of need for targeted Rx #LCSM smex-ctp.trendmicro.com/wis/clicktim...
smex-ctp.trendmicro.com
February 19, 2025 at 3:42 AM
Congratulations to Adel from @petermac for this analysis showing KRAS G12D patients are more likely to be non-smokers but also associated with low PDL1, comutations with TP53/STK11 and derive limited immunotherapy response. Area of need for targeted Rx #LCSM smex-ctp.trendmicro.com/wis/clicktim...
What a great pick for this year’s #lorneiandi Hertzog oration, David Underhill @cedarssinai.bsky.social presenting exciting research (recently published @nature.com !) identifying a role for PDL1 in binding fungi during phagocytosis. Shame @paulh1pjh.bsky.social couldn’t make it this year!
February 19, 2025 at 4:25 AM
What a great pick for this year’s #lorneiandi Hertzog oration, David Underhill @cedarssinai.bsky.social presenting exciting research (recently published @nature.com !) identifying a role for PDL1 in binding fungi during phagocytosis. Shame @paulh1pjh.bsky.social couldn’t make it this year!
Biomarker in BrCa session has me feeling biomarker angst. Lovely data re quality of immune response to anti-HER2 mAb predicting outcome (Sotiriou). But how to reconcile concept w HER2-low ADC data? Also PDL1 doesn't predict anti PDL1 benefit in TNBC. 'Obvious' targets = poor predictors. #AACR25
April 26, 2025 at 3:37 PM
Biomarker in BrCa session has me feeling biomarker angst. Lovely data re quality of immune response to anti-HER2 mAb predicting outcome (Sotiriou). But how to reconcile concept w HER2-low ADC data? Also PDL1 doesn't predict anti PDL1 benefit in TNBC. 'Obvious' targets = poor predictors. #AACR25
PDL1 Immune Marker Linked to Better Survival in Colon Cancer
www.thailandmedical.news/news/pdl1-im...
www.thailandmedical.news/news/pdl1-im...
PDL1 Immune Marker Linked to Better Survival in Colon Cancer - Thailand Medical News
www.thailandmedical.news
April 22, 2026 at 3:13 AM
PDL1 Immune Marker Linked to Better Survival in Colon Cancer
www.thailandmedical.news/news/pdl1-im...
www.thailandmedical.news/news/pdl1-im...
Oncology leads the way! 🚀
🧬 In 2024, the FDA approved ✅50 new therapies, with 15 (30%) 🎯targeting cancer – including multiple first-in-class therapies and the 11th PD1/PDL1 inhibitor.
@oncoalert.bsky.social #Oncology #FDAApprovals #Innovation
nature.com/articles/d4157…
🧬 In 2024, the FDA approved ✅50 new therapies, with 15 (30%) 🎯targeting cancer – including multiple first-in-class therapies and the 11th PD1/PDL1 inhibitor.
@oncoalert.bsky.social #Oncology #FDAApprovals #Innovation
nature.com/articles/d4157…
January 4, 2025 at 11:50 AM
Oncology leads the way! 🚀
🧬 In 2024, the FDA approved ✅50 new therapies, with 15 (30%) 🎯targeting cancer – including multiple first-in-class therapies and the 11th PD1/PDL1 inhibitor.
@oncoalert.bsky.social #Oncology #FDAApprovals #Innovation
nature.com/articles/d4157…
🧬 In 2024, the FDA approved ✅50 new therapies, with 15 (30%) 🎯targeting cancer – including multiple first-in-class therapies and the 11th PD1/PDL1 inhibitor.
@oncoalert.bsky.social #Oncology #FDAApprovals #Innovation
nature.com/articles/d4157…
Press release: phase III SKYSCRAPER-01 study negative for OS at final analysis. Adding anti-TIGIT tiragolumab to first line atezolizumab in advanced PDL1 high NSCLC did not improve PFS or OS. Now to dissect what happened between phase II and III.
www.gene.com/media/press-...
www.gene.com/media/press-...
Genentech: Press Releases | Monday, Nov 25, 2024
Discover the latest news about our company, our products, our policies, and our people.
www.gene.com
November 26, 2024 at 11:52 AM
Press release: phase III SKYSCRAPER-01 study negative for OS at final analysis. Adding anti-TIGIT tiragolumab to first line atezolizumab in advanced PDL1 high NSCLC did not improve PFS or OS. Now to dissect what happened between phase II and III.
www.gene.com/media/press-...
www.gene.com/media/press-...
Ich kenne zu Neuroendokrin Grosszellig keine Daten die den Effekt einer PDL1-Inhibition nachlegen. Kennst Du was?
April 26, 2026 at 6:14 PM
Ich kenne zu Neuroendokrin Grosszellig keine Daten die den Effekt einer PDL1-Inhibition nachlegen. Kennst Du was?
PDL1 is generally very weak and heterogeneous, making it difficult to image (given its importance clinically). Huang et al. optimized a high-dynamic-range (HDR) imaging method for immunofluorescence to assess PD-L1 expression. 🧪
November 18, 2024 at 1:38 PM
PDL1 is generally very weak and heterogeneous, making it difficult to image (given its importance clinically). Huang et al. optimized a high-dynamic-range (HDR) imaging method for immunofluorescence to assess PD-L1 expression. 🧪
#WeekendRead #NeuroimmunologyPower #ImmunometabolismPower #NotOnlyItaconate! Kang &co show Science Advances that #dopamine inhibits ACOD1 upregulation by TLR4/CREB1, preventing ACOD1 (not itaconate) dependent PDL1 induction, protecting against inflammation-induced #immunosuppression during #sepsis!
A neuroimmune pathway drives bacterial infection
Dysregulation of the dopamine-ACOD1 axis correlates with sepsis severity.
scim.ag
May 17, 2025 at 3:06 PM
#WeekendRead #NeuroimmunologyPower #ImmunometabolismPower #NotOnlyItaconate! Kang &co show Science Advances that #dopamine inhibits ACOD1 upregulation by TLR4/CREB1, preventing ACOD1 (not itaconate) dependent PDL1 induction, protecting against inflammation-induced #immunosuppression during #sepsis!
Gibt wohl schon was. Hast Du nur die Heidelberger als Onkologen? Gibt bei Dir doch bestimmt auch Niedergelassene.
April 26, 2026 at 6:19 PM
Gibt wohl schon was. Hast Du nur die Heidelberger als Onkologen? Gibt bei Dir doch bestimmt auch Niedergelassene.
1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25
March 27, 2025 at 4:03 PM
1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25
CD274 3’UTR deletion and genomically hardwired #PDL1 over expression as an adaptive survival mechanism to #atezolizumab.. ?specific mechanism to targeting the tumour side of the immune synapse #hemesky #hemepath
doi.org/10.1080/1042...
doi.org/10.1080/1042...
Genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
doi.org
December 27, 2024 at 7:33 AM
CD274 3’UTR deletion and genomically hardwired #PDL1 over expression as an adaptive survival mechanism to #atezolizumab.. ?specific mechanism to targeting the tumour side of the immune synapse #hemesky #hemepath
doi.org/10.1080/1042...
doi.org/10.1080/1042...
In 2018, with Tom Newsom-Davis, I wrote a chapter on novel immune check point targets for the ACP book ‘Problem Solving In Cancer Immunotherapy’. It’s fab to sit here and know my research wasn’t too far off and these targets now have drugs! Shobhit Baijal on ‘beyond PDL1/PD1 #BTOG25
March 3, 2025 at 2:42 PM
In 2018, with Tom Newsom-Davis, I wrote a chapter on novel immune check point targets for the ACP book ‘Problem Solving In Cancer Immunotherapy’. It’s fab to sit here and know my research wasn’t too far off and these targets now have drugs! Shobhit Baijal on ‘beyond PDL1/PD1 #BTOG25
This week's issue of #ScienceTranslationalMedicine is out!
A whole-genome test catches residual disease in patients with HPV-linked head and neck cancer, research reveals how immunity influences the premalignant origins of colon cancer, and more. https://scim.ag/4g9ZywP
A whole-genome test catches residual disease in patients with HPV-linked head and neck cancer, research reveals how immunity influences the premalignant origins of colon cancer, and more. https://scim.ag/4g9ZywP
June 10, 2026 at 9:00 PM
This week's issue of #ScienceTranslationalMedicine is out!
A whole-genome test catches residual disease in patients with HPV-linked head and neck cancer, research reveals how immunity influences the premalignant origins of colon cancer, and more. https://scim.ag/4g9ZywP
A whole-genome test catches residual disease in patients with HPV-linked head and neck cancer, research reveals how immunity influences the premalignant origins of colon cancer, and more. https://scim.ag/4g9ZywP
#ESMOGI25: A combination of givastomig, nivolumab and mFOLFOX shows promising activity and acceptable safety in HER2− CLDN18.2+ #GastroEsophagealCancer, regardless of #PDL1 or CLDN18.2 status.
Further details in the #ESMODailyReporter
🔗 buff.ly/hKBZtJZ
Further details in the #ESMODailyReporter
🔗 buff.ly/hKBZtJZ
July 2, 2025 at 3:10 PM
#ESMOGI25: A combination of givastomig, nivolumab and mFOLFOX shows promising activity and acceptable safety in HER2− CLDN18.2+ #GastroEsophagealCancer, regardless of #PDL1 or CLDN18.2 status.
Further details in the #ESMODailyReporter
🔗 buff.ly/hKBZtJZ
Further details in the #ESMODailyReporter
🔗 buff.ly/hKBZtJZ
#ScienceSaturday CD28 is an important costimulatory molecule for T cells. However, in a recent study, Yang et al utilized a whole genome CRISPR screen in a breast cancer model to identify that tumors can also use CD28 signaling to inhibit T cells through upregulation of PDL1 on the tumor surface.
December 15, 2024 at 12:52 AM
#ScienceSaturday CD28 is an important costimulatory molecule for T cells. However, in a recent study, Yang et al utilized a whole genome CRISPR screen in a breast cancer model to identify that tumors can also use CD28 signaling to inhibit T cells through upregulation of PDL1 on the tumor surface.
Prof @lesinskilab.bsky.social #cancer #immunotherapy expert #Emory Univ. Talks strategy to treat #cholangiocarcinoma / #MEKi & #PDL1 /MEMi incr CD8/FOXP3 /T cells activ also reduced/CT26 + #4-1BB MEKi / or #CD27 in mel/ #Bridge2024 @sitcancer.bsky.social @chrystalpaulos.bsky.social
December 5, 2024 at 9:24 AM
Prof @lesinskilab.bsky.social #cancer #immunotherapy expert #Emory Univ. Talks strategy to treat #cholangiocarcinoma / #MEKi & #PDL1 /MEMi incr CD8/FOXP3 /T cells activ also reduced/CT26 + #4-1BB MEKi / or #CD27 in mel/ #Bridge2024 @sitcancer.bsky.social @chrystalpaulos.bsky.social
Quantifying PD1 saturation by PDL1 in tumor tissue using a novel RNA aptamer-based assay https://www.biorxiv.org/content/10.64898/2026.04.06.716702v1
April 9, 2026 at 12:16 AM
Quantifying PD1 saturation by PDL1 in tumor tissue using a novel RNA aptamer-based assay https://www.biorxiv.org/content/10.64898/2026.04.06.716702v1